^
    Back
    Association details:
    Biomarker:SETBP1 mutation
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Aging (Albany NY)
    Title:

    SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC

    Published date:
    08/02/2023
    Excerpt:
    We first explored the ICI prognostic roles of SETBP1 mutations in pooled melanoma patients. Kaplan-Meier results showed that SETBP1 mutated (SETBP1-MUT) melanoma patients exhibited a markedly improved ICI survival benefit than wild-type patients (median survival time: 49.3 vs. 25.6 months, Log-rank test P < 0.001; Figure 2A).
    DOI:
    https://doi.org/10.18632/aging.204913